#ACR21 L16 - Breakthrough #COVID19 in rheum pts ⭐️Breakthrough ifn ~4%, compared to 3% wo rheum disease. Statistically signif ⬆️ risk in RA, gout, polymyositis, vasculitis, multiple rheum disease ⭐️bDMARD, multiple AIRD risks @Rheumnow https://t.co/cuM9LcEr4u https://t.co/Los2n7BoIn